Date: 2014-05-31
Type of
information: Presentation of results at a congress
phase: 2
Announcement: presentation of results at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 to June 3, 2014, in Chicago
Company: Genentech, a member of the Roche Group (USA - Switzerland) Seattle Genetics (USA - WA)
Product: polatuzumab vedotin, pinatuzumab vedotin
Action
mechanism:
- antibody drug conjugate. Polatuzumab vedotin (Anti-CD79b, DCDS4501A, RG7596) is an antibody drug conjugate (ADC) composed of a monoclonal antibody directed against CD79b, link to the cytotoxic, microtubule-disrupting agent, monomethyl auristatin E (MMAE). Polatuzumab vedotin is designed to selectively bind to CD79b on hematologic cells.
- Pinatuzumab vedotin (Anti-CD22, DCDT2980S, RG7593) is an antibody drug conjugate (ADC) composed of a monoclonal antibody directed against CD22, link to monomethyl auristatin E (MMAE). Pinatuzumab vedotin is designed to selectively bind to CD22 on hematologic cells.
- Polatuzumab vedotin (anti-CD79b) and pinatuzumab vedotin (anti-CD22) are being developed by Genentech consisting of an anti-CD79b or anti-CD22 monoclonal antibody conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) using Seattle Genetics’ ADC technology.
Disease: relapsed/refractory non-Hodgkin lymphoma
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On May 31, 2014, Seattle Genetics announced data from several collaborator antibody-drug conjugate (ADC) programs presented at the American Society of Clinical Oncology(ASCO) 50th Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL. Genentech, a member of the Roche Group, is presenting data from five ADC programs, including two oral presentations. Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (Abstract #8519,) were reported evaluating the activity and safety of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in 59 and 63 patients, respectively, with relapsed or refractory non-Hodgkin lymphoma (NHL). Both polatuzumab vedotin and pinatuzumab vedotin demonstrated antitumor activity with similar and generally acceptable safety profiles. In the analysis, durable responses were observed in both diffuse large b-cell lymphoma (DLBCL) and follicular lymphoma, including patients who were refractory to rituximab and/or their most recent therapy. Treatment with polatuzumab vedotin plus rituximab demonstrated an objective response of 56 percent (22 of 39 patients) in DLBCL and 70 percent (14 of 20 patients) in follicular lymphoma. Treatment with pinatuzumab vedotin plus rituximab demonstrated an objective response of 57 percent (24 of 42 patients) in DLBCL and 62 percent (13 of 21 patients) in follicular lymphoma. The phase 2 study is ongoing and further studies evaluating polatuzumab vedotin combined with chemotherapy are planned.
Is
general: Yes
